Profound Medical Corp. PROF
6.88 USD -0.28 (-3.91%)
At closeNov 5, 2026, 4:00 PM EST
6.88 0.00 0.00%
After hours · Nov 5, 4:00 PM ET
6.69 Day range 7.39
4.80 52-week range 8.95
- YTD
- -12.58%
- 1 year
- +17.41%
News
zacks.com Profound Medical (PROF) Expected to Beat Earnings Estimates: Should You Buy? Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…
zacks.com Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable,…
benzinga.com Profound Medical Strikes Supply, Distribution Deal With iMRI Division Of Cook Medical To Expand Sales Of TULSA-PRO System In U.S. Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI
globenewswire.com Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach
globenewswire.com Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let's Huddle' Webinar TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that Emmy Award-winning television host, health advocate and…
zacks.com Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect? The mean of analysts' price targets for Profound Medical (PROF) points to a 58.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
globenewswire.com TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI…
zacks.com Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength? Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price…
benzinga.com Profound Medical Signs Agreement With Telix Pharmaceuticals To Educate Urologists, Radiologists, Nuclear Medicine Physicians, Prostate Cancer Centers Over Roles Of Telix’s Advanced Prostate-Specific Membrane Antigen Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures,
globenewswire.com Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $207.5 million. Haemonetics (NYSE:HAE) stock…
benzinga.com Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98%…
benzinga.com Profound Medical Reports Q3 Preliminary Revenue Range $9.8M - $10M, Up ~85% To 89% YoY Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today
globenewswire.com Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding…
globenewswire.com Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative…
benzinga.com Profound Medical Appoints Richard Fabian As President, Effective Immediately, Succeeding Mathieu Burtnyk Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today
globenewswire.com Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative…
globenewswire.com Profound's Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days' Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day Most recent TDC software provides a potential roadmap for customers…
globenewswire.com Profound Medical Announces Management Change TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative…
globenewswire.com Profound Medical Launches ‘Let's Huddle', a Global Community Supporting Men Throughout Their Prostate Care Journey A patient-centered initiative focused on education, connection, and support A patient-centered initiative focused on education, connection, and support
marketbeat.com Profound Medical Q2 Earnings Call Highlights Profound Medical NASDAQ: PROF reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing…
zacks.com Profound Medical (PROF) Q2 Earnings Surpass Estimates Profound Medical (PROF) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.52 per share a year ago.
benzinga.com Profound Medical Affirms FY2026 Sales Guidance of $25.000M vs $26.858M Est Profound Medical (NASDAQ:PROF) affirms FY2026 sales outlook from $25.000 million to $25.000 million vs $26.858 million estimate.
benzinga.com Profound Medical Q2 EPS $(0.26), Inline, Sales $2.483M Miss $5.500M Estimate Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.52) per share from the same…
globenewswire.com Profound Medical Reports Second Quarter 2026 Financial Results – Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong…
globenewswire.com Robotic Radical Prostatectomy Comes Up ‘Short' in CAPTAIN Trial – Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservation compared to robotic RP at 1 month – – Whole-gland TULSA ablation demonstrates statistically…
globenewswire.com Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative…
globenewswire.com Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026 TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and…
zacks.com Profound Medical (PROF) Moves 8.2% Higher: Will This Strength Last? Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength…
benzinga.com Telix Pharma Enters Into LOI To Pursue Collaborations With EDAP And Profound Medical To Explore Investigational Use Of Telix's PSMA-PET1 Imaging Agents Gozellix And Illuccix With Robotic HIFU, And Other Image-Guided Therapies To Treat Prostate Cancer Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and…- benzinga.com Profound Medical Q1 EPS $(0.19) Beats $(0.35) Estimate, Sales $5.337M Miss $6.648M Estimate Profound Medical (TSX:PRN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.35) by 45.71 percent. This is a 47.22 percent increase over losses of…
benzinga.com Profound Medical To Highlight Interventional MRI TULSA Procedure In Several Presentations At 2026 SIR Annual Scientific Meeting Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
benzinga.com Top 3 Health Care Stocks That Are Set To Fly In March Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strength on up and down days. Here's a list of oversold stocks with RSI near or below 30.- benzinga.com Profound Medical Announces Level 1 Post-Market CAPTAIN Trial Comparing TULSA Procedure With Robotic RP Meets Primary Safety Endpoint In Grade Group 2 And 3 Prostate Cancer – First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment –– TULSA…
benzinga.com Profound Medical Q4 Earnings Assessment 
benzinga.com Earnings Summary: Profound Medical Q4 - benzinga.com Profound Medical Q4 EPS $(0.27) Misses $(0.26) Estimate, Sales $5.977M Miss $7.233M Estimate Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 35 percent decrease over losses of…
benzinga.com Earnings Scheduled For March 5, 2026 
benzinga.com Profound Medical's Earnings: A Preview - benzinga.com Profound Medical Announces First Prostate Cancer Patient Treated With TULSA-PRO At Mount Sinai Hospital Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual functionThe Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World…
- benzinga.com Lake Street Maintains Buy on Profound Medical, Raises Price Target to $12 Lake Street analyst Benjamin Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and raises the price target from $11 to $12.
- benzinga.com Profound Medical Announces First Non‑Trial Prostate Cancer Patient Treated With TULSA‑PRO At Johns Hopkins Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
benzinga.com Profound Medical Prices $40M Common Stock Offering Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering…- benzinga.com Profound Medical To Launch TULSA-AI Volume Reduction Module For Optimizing Treatment Of Patients With Benign Prostatic Hyperplasia, Or Enlarged Prostate, At RSNA Meeting Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
- benzinga.com Profound Medical Q3 EPS $(0.26) Beats $(0.36) Estimate, Sales $5.289M Beat $4.995M Estimate Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.36) by 28.77 percent. This is a 31.58 percent increase over losses of…
- benzinga.com Earnings Scheduled For November 13, 2025
- benzinga.com Profound Medical Signs Distribution, Supply Agreement For Its TULSA-PRO System With Getz Healthcare In Australia, New Zealand Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free…
- benzinga.com Profound Medical Enters Into Exclusive Distribution Agreement for TULSA-PRO And Sonalleve With Al Faisaliah Medical Systems In Saudi Arabia Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets artificial intelligence ("AI")-powered, MRI-guided,…